Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? (Q38104610)

28 August 2017

title

Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? (English)

1 reference

28 August 2017

main subject

irritable bowel syndrome

1 reference

Patrick A Hughes

1 reference

28 August 2017

Heddy Zola

1 reference

28 August 2017

Irmeli A Penttila

1 reference

28 August 2017

L Ashley Blackshaw

1 reference

28 August 2017

Jane M Andrews

1 reference

28 August 2017

Doreen Krumbiegel

1 reference

28 August 2017

language of work or name

English

0 references

publication date

7 May 2013

1 reference

The American Journal of Gastroenterology

28 August 2017

published in

1 reference

28 August 2017

volume

108

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

1066-1074

1 reference

Functional bowel disorders

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Post-inflammatory colonic afferent sensitisation: different subtypes, different pathways and different time courses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Post-inflammatory modification of colonic afferent mechanosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Diversity of the human intestinal microbial flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The gaseous mediator, hydrogen sulphide, inhibits in vitro motor patterns in the human, rat and mouse colon and jejunum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The endogenous hydrogen sulfide producing enzyme cystathionine-beta synthase contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Sensitization of mesenteric afferents to chemical and mechanical stimuli following systemic bacterial lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Bacterial cell products signal to mouse colonic nociceptive dorsal root ganglia neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

A Pilot Study of Fecal Serine-Protease Activity: A Pathophysiologic Factor in Diarrhea-Predominant Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Chlamydia trachomatis antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Probiotics in functional gastrointestinal disorders: what are the facts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Increased proteasome-mediated degradation of occludin in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Altered peripheral toll-like receptor responses in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Role for protease activity in visceral pain in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Immunomodulatory mast cells: negative, as well as positive, regulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Mucosal cytokine imbalance in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Differential expression of toll-like receptors in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Protective and pathogenic functions of macrophage subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Immune dysfunction in patients with functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Implications of eosinophilia in the normal duodenal biopsy - an association with allergy and functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

T-cell activation in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Immune activation in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Serum and colonic mucosal immune markers in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Helper T cell diversity and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

CD4+CD25+ regulatory T cells in irritable bowel syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Autoantibodies in patients with gut motility disorders and enteric neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Anti-enteric neuronal antibodies and the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Disruption of intestinal motility by a calcium channel-stimulating autoantibody in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Prolonged IL-1beta exposure alters neurotransmitter and electrically induced Ca(2+) responses in the myenteric plexus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

TRPV1-expressing sensory fibres and IBS: links with immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Immune cell–derived opioids protect against neuropathic pain in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

The control of pain in peripheral tissue by opioids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Opioid receptors in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Abdominal pain in Irritable Bowel Syndrome: A review of putative psychological, neural and neuro-immune mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Human visceral afferent recordings: preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.120

21 January 2018

Identifiers

DOI

10.1038/AJG.2013.120

1 reference

Dimensions Publication ID

28 August 2017

1050015156

0 references

1 reference